Clinical Trial Search

Primary: Number of Participants With a 50 Percent Decrease in Mean Stool Count — 17 Participants

Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants

Primary: Mean Change From Baseline in Blood Lead Levels During the Treatment Period and Post-treatment Follow-up Period — 0.120; 0.306; 0.095; 0.359 nanograms per millilitre…

Primary: Diarrhea for >= 2 Consecutive Days — 68; 69.6; 65.2; 72.2 percentage of patients

Primary: Duration of Diarrhea in Acute Diarrheal Illnesses in a Developed Nation While Taking Zinc or Placebo. — 73; 72; 48; 76.8 Hours — p=0.88

Primary: Stool Output Volume During Treatment Period. — 9.82; 9.31; 5.69; 7.29 ml/kg·h-1 — p=0.003

Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78

Primary: Global Improvement Scale — 4.3; 4.3 units on a scale — p=0.26

Primary: Stool Output — 4769; 4742; 1688; 1704 gram — p=0.9941

Primary: Fasting Serum C4 Levels — 2.2; 50.4 ng/ML

Primary: Time (in Hours) Between the 1st Intake of IQP-MM-101 and First Formed or Hard Stool (Type 6 to 1) Followed by a Non Watery Stool (Type 6 to 1) — 21.30 hours

Primary: Change of Mucus and Mucin Secretion in Patients With Chronic Constipation and in Controls. — 260; 133; 229; 161 mg/hour

Primary: Percentage of Patients Having Minimum Reduction of 50% or Normalization (≤3 Stools/24hours) in the Mean Number of Stools (Mean of Last 7 Days) — 44.4; 55.6 Percentage of…

Primary: Diarrheal Stool Output Rate — 25.42; 32.57 mL/hour — p=0.2254

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). — 189; 20 Participants

Primary: Reduction in Frequency of Defecation to 3 Times Per Day — 118; 24 Participants

Primary: Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Compared to Healthy Subjects — 8.3; 17.7 mg*h/dL — p=<0.001

Primary: Maximum Severity of Diarrhea Toxicity as Measured by the CTCAE v4.0 During and After Radiotherapy (RT) — 10; 10; 13; 15 Participants — p=0.41

Primary: Colonic-Mucosa Associated Microbial Species Per Compiled Participants in 5 Different Arms — 40; 30; 23; 23 microbial species population

Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…

Primary: Duration of Diarrhea — 2; 2 days — p=0.43

Primary: Baseline Gastrointestinal Symptom Rating Scale (GSRS) Score — 2.7; 2.8 Score on a scale

Primary: % of Subjects With Treatment Emergent Adverse Events — 108 Participants

Primary: Changes in GIS Scores Between Baseline and After a 12 Week Intervention With Mesalamine or Placebo — 2.72; 2.22 units on a scale — p=.001

Primary: Repeat Treatment Responders — 32.6; 25.0 percentage of patients — p=0.0232

Primary: Incidence of Adverse Events — 1; 1; 0; 1 events

Primary: Duration of Diarrhea (Hours) Between the Start of Treatment Until Last Diarrheal/Watery Stool Before Recovery or End of Study Treatment (Treatment Duration Maximal 5…

Primary: Change From Baseline in Average Bristol Stool Form Scale (BSFS) Score Over 4 Weeks of Treatment Period — 5.89; 5.34; -1.25; -1.09 score on a scale

Primary: Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks). — 35.7; 34.7…

Primary: Colonic Geometric Center at 24 Hours (GC24) — 3.1; 3.5; 2.2 units on a scale